Notch signaling, γ-secretase inhibitors, and cancer therapy

被引:355
作者
Shih, Ie-Ming
Wang, Tian-Li
机构
[1] Johns Hopkins Med Inst, Dept Gynecol, Baltimore, MD 21231 USA
[2] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21231 USA
[3] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21231 USA
关键词
TRANSGENIC MICE; ACTIVATION; TUMOR; TARGET; CELLS; LEUKEMIA/LYMPHOMA; OVEREXPRESSION; PRESENILIN; MUTATIONS;
D O I
10.1158/0008-5472.CAN-06-3958
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Notch signaling pathway represents a critical component in the molecular circuits that control cell fate during development. Aberrant activation of this pathway contributes to tumorigenesis. The role of Notch in human cancer has been highlighted recently by the presence of activating mutations and amplification of Notch genes in human cancer and by the demonstration that genes in the Notch signaling pathway could be potential therapeutic targets. It has become clear that one of the major therapeutic targets in the Notch pathway are the Notch receptors, in which T-secretase inhibitors prevent the generation of the oncogenic (intracellular) domain of Notch molecules and suppress the Notch activity. This review article summarizes the biological roles of Notch molecules in cancer development with special emphasis on the promise and challenges in applying gamma-secretase inhibitors as a new line of targeted therapeutic agents.
引用
收藏
页码:1879 / 1882
页数:4
相关论文
共 25 条
[1]   Endogenous β-amyloid production in presenilin-deficient embryonic mouse fibroblasts [J].
Armogida, M ;
Petit, A ;
Vincent, B ;
Scarzello, S ;
da Costa, CA ;
Checler, F .
NATURE CELL BIOLOGY, 2001, 3 (11) :1030-1033
[2]   Notch signaling: Cell fate control and signal integration in development [J].
Artavanis-Tsakonas, S ;
Rand, MD ;
Lake, RJ .
SCIENCE, 1999, 284 (5415) :770-776
[3]   Deregulated NOTCH signaling in acute T-cell lymphoblastic leukemia/lymphoma: New insights, questions, and opportunities [J].
Aster, JC .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2005, 82 (04) :295-301
[4]   γ-secretase inhibitors for Alzheimer's disease: Balancing efficacy and toxicity [J].
Barten D.M. ;
Meredith Jr. J.E. ;
Zaczek R. ;
Houston J.G. ;
Albright C.F. .
Drugs in R&D, 2006, 7 (2) :87-97
[5]   Constitutive activation of NF-κB and T-cell leukemia/lymphoma in Notch3 transgenic mice [J].
Bellavia, D ;
Campese, AF ;
Alesse, E ;
Vacca, A ;
Felli, MP ;
Balestri, A ;
Stoppacciaro, A ;
Tiveron, C ;
Tatangelo, L ;
Giovarelli, M ;
Gaetano, C ;
Ruco, L ;
Hoffman, ES ;
Hayday, AC ;
Lendahl, U ;
Frati, L ;
Gulino, A ;
Screpanti, I .
EMBO JOURNAL, 2000, 19 (13) :3337-3348
[6]   Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells [J].
Curry, CL ;
Reed, LL ;
Golde, TE ;
Miele, L ;
Nickoloff, BJ ;
Foreman, KE .
ONCOGENE, 2005, 24 (42) :6333-6344
[7]   Notch3 signaling initiates choroid plexus tumor formation [J].
Dang, L ;
Fan, X ;
Chaudhry, A ;
Wang, M ;
Gaiano, N ;
Eberhart, CG .
ONCOGENE, 2006, 25 (03) :487-491
[8]   Chromosome 19 translocation, overexpression of Notch3, and human lung cancer [J].
Dang, TP ;
Gazdar, AF ;
Virmani, AK ;
Sepetavec, T ;
Hande, KR ;
Minna, JD ;
Roberts, JR ;
Carbone, DP .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (16) :1355-1357
[9]  
DE SB, 1999, NATURE, V398, P518
[10]   The mouse mammary tumor associated gene INT3 is a unique member of the NOTCH gene family (NOTCH4) [J].
Gallahan, D ;
Callahan, R .
ONCOGENE, 1997, 14 (16) :1883-1890